StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.06 | $1.02 | -3.77% | 0.1M |
| 05-12 | $1.02 | $1.05 | +2.94% | 0.1M |
| 05-13 | $1.06 | $1.07 | +0.94% | 0.1M |
| 05-14 | $1.07 | $1.08 | +0.93% | 0.1M |
| 05-15 | $1.08 | $1.09 | +0.93% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for ABVC.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for ABVC.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2024 2024-12-31 | Annual 2015 2015-12-31 |
|---|---|---|---|---|
Revenue | $296.00K | $795.95K | $0.00 | $50.00M |
Operating Income | $-7.15M | $-4.95M | $-4.71M | $-3.50M |
Net Income | $-7.91M | $-5.14M | $-4.90M | $-3.50M |
EPS (Diluted) | $-0.39 | $-0.28 | $-0.42 | $-0.02 |
Total Assets | $21.06M | $21.21M | $7.54M | $64.91K |
Total Liabilities | $7.76M | $6.72M | $6.82M | Not available |
Cash & Equivalents | $681.48K | $192.07K | $248.38K | $423.96K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 25.05M | 24.19M | 13.87M | 65.43M |
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.